Do Beta-Blockers Actually Change What Your Wearable Shows?
The assumption seems obvious. The two studies that actually tested it, using real wearable data, didn't confirm it.
This piece covers what real studies using wearable or Holter-derived heart rate and HRV data found when comparing beta-blocker use against an alternative or against no medication. It does not cover beta-blockers' broader, well-established cardiovascular benefits, which are a separate clinical question from what a wrist-worn device specifically registers.
The assumption that beta-blockers, drugs that blunt the effect of adrenaline on the heart, should obviously slow heart rate and shift HRV on a wearable seems like it shouldn't need testing. Two real studies that tested it directly with actual wearable or Holter data found something more complicated than that assumption predicts. Heart rate collected from consumer wearables in older patients with atrial fibrillation and heart failure, randomized to either digoxin or a beta-blocker, was compared directly in a trial published in Nature Medicine, finding no statistically significant difference in wearable-measured heart rate between the two drugs. A separate retrospective study comparing HRV parameters after a heart procedure between a low-dose-metoprolol group and a no-medication group found no significant difference there either. Neither result means beta-blockers don't work or don't affect the heart, both drugs studied here work by different mechanisms toward the same rate-control goal, and the comparison in each study was against an active alternative or no intervention in a specific patient population, not a clean beta-blocker-versus-nothing test in healthy wearable users.
A mechanism that sounds like it should be obvious
Beta-blockers work by blocking beta-adrenergic receptors, blunting the heart's response to adrenaline and the broader sympathetic nervous system. Since HRV is itself a reflection of the balance between sympathetic and parasympathetic nervous system activity, the intuitive prediction writes itself: less sympathetic drive should mean a measurably different heart rate and HRV pattern, something a wearable's continuous heart-rate sensor should be able to pick up.
That intuitive chain of reasoning is real physiology, but it's a prediction, not a finding. The question this piece asks is narrower and more specific: when researchers actually pointed a wearable or a Holter monitor at real patients on a beta-blocker and checked, did the numbers move the way the mechanism predicts.
2 studies
- In the RATE-AF trial, 53 older patients (mean age 75.6) with permanent atrial fibrillation and heart failure were randomized to digoxin or a beta-blocker and wore a wrist device linked to a smartphone for 20 weeks, generating over 143 million heart-rate data points. Heart rate in the beta-blocker group was not significantly different from the digoxin group (adjusted regression coefficient 0.66, 95% CI -3.45 to 4.77, P=0.75), including after accounting for physical activity level.
- In patients with paroxysmal atrial fibrillation who underwent a pulmonary vein isolation procedure, 24-hour Holter-derived HRV parameters were compared between a group taking low-dose sustained-release metoprolol (23.75 mg/day) and a group taking no antiarrhythmic medication. No significant differences in HRV parameters were observed between the two groups at any follow-up point.
Why a null result here doesn't mean the drug isn't working
Neither study compared a beta-blocker against nothing at all in an otherwise healthy person, the comparison a lot of people asking this question are actually picturing. RATE-AF compared it against digoxin, a different rate-controlling drug being used for the same clinical purpose in the same patient population, so a null result there means the two drugs performed similarly on wearable-measured heart rate, not that neither drug affects heart rate at all. The metoprolol study used a very low dose (23.75 mg/day) in a narrow post-procedure population, where the underlying cardiac rhythm had also just been surgically altered, a genuinely different physiological starting point than a healthy person starting a beta-blocker for, say, anxiety or migraine prevention.
Beta-blockers' broader cardiovascular benefits, including in heart failure specifically, are supported by a large, separate body of evidence unrelated to what a wrist-worn sensor happens to register day to day. What these two studies actually narrow down is a much more specific claim: whether the drug's effect is reliably visible in the specific, noisy, real-world heart-rate stream a consumer wearable collects, in the particular populations and comparisons each study used.
Both real studies found here used a comparison group, not a no-treatment baseline in healthy adults. Whether a healthy person starting a beta-blocker for a non-cardiac reason would see an obvious shift in their own wearable's HRV or heart rate isn't directly answered by either study, and no study matching that specific, common real-world scenario was found during research for this piece.
How this differs from the site's existing RHR-and-drugs coverage
The existing does lowering resting heart rate with drugs reduce mortality risk piece covers a broader, longer-horizon question: whether pharmacologically lowering RHR, tracked over months in registries and trials, changes mortality outcomes. This piece is narrower and more immediate: whether the specific act of taking a beta-blocker produces a detectable shift in what a consumer wearable itself registers, tested directly against real wearable and Holter data rather than clinical outcome registries.
The two pieces share a theme, drugs that affect heart rate, but ask genuinely different questions: one is about long-run health outcomes, this one is about whether a specific, everyday assumption about a device's readout actually holds up against the studies that checked.
Common questions
Do beta-blockers lower the heart rate number shown on a smartwatch or fitness tracker?
The two real studies that tested this directly with wearable or Holter data both found no statistically significant difference when comparing a beta-blocker against an alternative drug or against no medication in the specific populations studied. This doesn't mean beta-blockers have no effect on heart rate broadly, only that these particular comparisons didn't detect one in wearable-collected data.
Why wouldn't a beta-blocker show up on a wearable if it blocks adrenaline's effect on the heart?
The physiological mechanism is real, but the two studies that tested it compared beta-blockers against an active alternative (digoxin) or in a narrow post-procedure population, not against no treatment in a healthy person. That comparison design, not necessarily the drug's real effect, may explain why no significant difference showed up.
Is there a study on healthy people starting a beta-blocker and their wearable's HRV changing?
No study matching that specific scenario, a healthy adult starting a beta-blocker with before-and-after wearable HRV data, was found during research for this piece. The available evidence comes from atrial fibrillation and post-cardiac-procedure populations instead.
Does this mean beta-blockers don't work?
No. Beta-blockers' cardiovascular benefits, including in heart failure, are supported by a large separate body of clinical evidence. These two studies narrow a much more specific question, whether that effect reliably shows up in real-world wearable heart-rate data, not whether the drug works clinically.
Sources
- Consumer wearable devices for evaluation of heart rate control using digoxin versus beta-blockers: the RATE-AF randomized trial.
- Effects of low-dose metoprolol succinate sustained-release tablets on patients with paroxysmal atrial fibrillation undergoing circumferential pulmonary vein isolation: a retrospective cohort study.